WELCOME TO The PHARMACEUTICAL REPORT
EnvisionPharmacies (formerly Orchard Pharmaceutical Services)
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
NovaBay Pharmaceuticals | July 20, 2021
NovaBay Pharmaceuticals, Inc., a pharmaceutical firm focused on commercializing Avenova for the eye care market, has announced a collaboration with ImprimisRx, one of the nation's top ophthalmology-focused pharmaceutical companies, to promote prescription Avenova. ImprimisRx, a wholly-owned subsidiary of Harrow Health, Inc., will offer national sales, marketing, and distribution support for NovaBay's FDA-cleared 0.01% hypochlorous acid Avenova in 40 ml bottles. Avenova is a clinically ap...
Alliance for Regenerative Medicine | July 07, 2020
The Alliance for Regenerative Medicine (ARM), the leading international advocacy organisation dedicated to realising the promise of regenerative medicines and advanced therapies, today published its response to the EU Pharmaceutical Strategy Roadmap which is designed to improve and accelerate patients’ access to safe and affordable medicines and to support innovation in the EU pharmaceutical industry. The full response can be found on the European Commission website.
Digital Pharmacist | October 11, 2021
Vow, a leading provider of interactive phone systems to the pharmacy industry, announced its strategic partnership with Digital Pharmacist, a software company that powers digital communication and adherence solutions for over 7,000 pharmacies. Together, the combined businesses establish an industry leading portfolio of solutions that automate pharmacy operations and enhance patient communications through its core solutions: Patient Engagement Platform, interactive voice response (IVR), website, ...
Eli Lilly | November 11, 2020
The U.S. just had another COVID-19 drug authorized for emergency use. But the approval is limited—and, with at least one vaccine launch on the horizon, industry watchers wonder whether drugs to treat the illness have any staying power. The FDA authorized Eli Lilly’s bamlanivimab for emergency use on Monday, making it the first antibody therapy to win that distinction. Dubbed LY-CoV555, it's an anti-SARS-CoV-2 antibody therapy the Indianapolis pharma is co-developing with AbCeller...
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE